Project Acronym:
IBD-Character

Project Reference:
305676

Duration: 52 months

Contract Type:
Small or medium-scale
focused research project

Project Funding:
6 million euros

Research area:
HEALTH.2012.2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joint and/or digestive system

This project has received funding from the European Union's Seventh Framework Program for research, technological development and demonstration under grant agreement #305676

Protein profiling

Proseek Multiplex – measure 92 biomarkers in 1µl of sample without compromising data quality

To enable identification and understanding of molecular and cellular pathways involved in initiation of the diseases we will develop novel and improved methods for large scale sensitive affinity proteomics based on partner Olink’s proprietary Proximity Extension Assay (PEA) technology. Initially developed in the FP7 program Proactive it is now made available and sold under the trade name Proseek Multiplex. In this project we will build dedicated multiplexed panels targeting proteins of interest for IBD. 

Our hypothesis is that (i) large numbers of protein biomarkers must be screened in order to find the best panels of relevant diagnostic markers, (ii) individual protein biomarkers will not be sufficient as diagnostic marker and (iii) informative tissue leakage protein biomarkers will be present at low concentration in circulation. Current multiplexed protein formats are limited either by their low sensitivity, low throughput or applicability for clinical testing, or all three. Therefore we aim to utilize Proseek multiplex, a multiplexed protein assay capable of detecting low abundant protein biomarkers in high throughput format.

Proseek Multiplex is based on the PEA developed at Olink. PEA has a major advantage over conventional multiplex immunoassays in that only correctly matched antibody pairs give rise to a signal. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules. When binding to their correct targets, they give rise to new DNA amplicons each ID-barcoding their respective antigens. The amplicons are subsequently quantified by high throughput real-time PCR. 

Proseek® Multiplex can provide accurate quantification of up to 92 proteins in one run at low to sub picogram per milliliter levels from1 µl samples such as serum or tissue lysates.

http://www.olink.com/products/proseek-multiplex/proseek-multiplex-oncology-i-v2
http://www.olink.com/products/proseek-multiplex/proseek-multiplex-cvd-i
http://www.olink.com/products/proseek-multiplex/proseek-multiplex-inflammation-i